William Blair Investment Management LLC decreased its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 902,611 shares of the company’s stock after selling 3,738 shares during the period. William Blair Investment Management LLC’s holdings in Inspire Medical Systems were worth $167,326,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the business. Harbour Investments Inc. boosted its stake in Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after buying an additional 99 shares during the period. Monimus Capital Management LP bought a new stake in Inspire Medical Systems during the fourth quarter valued at $5,099,000. Commonwealth Equity Services LLC boosted its stake in Inspire Medical Systems by 7.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 7,984 shares of the company’s stock valued at $1,480,000 after buying an additional 575 shares during the period. Swiss National Bank boosted its stake in Inspire Medical Systems by 1.0% during the fourth quarter. Swiss National Bank now owns 58,600 shares of the company’s stock valued at $10,863,000 after buying an additional 600 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Inspire Medical Systems by 21.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 177,588 shares of the company’s stock valued at $32,921,000 after purchasing an additional 31,344 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.
Inspire Medical Systems Trading Up 2.2 %
INSP opened at $162.26 on Monday. The company has a market cap of $4.81 billion, a P/E ratio of 93.79, a P/E/G ratio of 2.86 and a beta of 1.48. The business’s 50-day moving average price is $184.92 and its 200-day moving average price is $192.07. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Wells Fargo & Company lowered their price target on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Bank of America upgraded Inspire Medical Systems from a “neutral” rating to a “buy” rating and raised their price target for the company from $220.00 to $255.00 in a research report on Wednesday, November 20th. Robert W. Baird lowered their price target on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 11th. KeyCorp restated an “overweight” rating and set a $234.00 price target (down previously from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $228.82.
Get Our Latest Analysis on INSP
Insider Activity at Inspire Medical Systems
In other news, insider Randy Ban sold 25,584 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO John Rondoni sold 583 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares of the company’s stock, valued at $1,777,187.76. This represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,225 shares of company stock worth $4,806,530 in the last 90 days. Company insiders own 4.10% of the company’s stock.
About Inspire Medical Systems
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
Featured Articles
- Five stocks we like better than Inspire Medical Systems
- Are Penny Stocks a Good Fit for Your Portfolio?
- How to Build the Ultimate Everything ETF Portfolio
- How to Invest in the Best Canadian StocksĀ
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 3 Monster Growth Stocks to Buy Now
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP – Free Report).
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.